R

Repligen Corp

XNAS · Laboratory Analytical Instruments · S&P 500

$145.49

-$1.86 (-1.26%) today

Open $147.35 High $149.38 Low $144.36 Vol 887K Avg $146.67

Related Stocks

Find similar stocks by technical condition — S&P 500 universe

Symbol Company Name Exchange Currency Category
LIMN Liminatus Pharma, Inc. Class A Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CMPX Compass Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
EXOZ eXoZymes Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PHGE BiomX Inc. XASE USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SANA Sana Biotechnology, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SGMO Sangamo Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PCVX Vaxcyte, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
TECH Bio-Techne Corp. XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CELZ Creative Medical Technology Holdings, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
MGTX MeiraGTx Holdings plc Ordinary Shares XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

52-week price range

$100.99 $175.77

Price is 44.1% above its 52-week low and 17.2% below its 52-week high. Trading in the upper half of its annual range — closer to the peak than the base.

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

  • Primary Exchange: XNAS
  • Market Cap: 6671470121.46
  • Address:
  • Category: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
  • Total Employees: 2000
  • Listing Date: 1986-04-29